clinical trial · NCT00650416
Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
HealthyCarvedilol Tablets 12.5 mgCoreg® Tablets 12.5 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's carvedilol 12.5 mg tablets to GSK's Coreg® 12.5 mg tablets following a single, oral 12.5 mg (1 x 12.5 mg) dose administered under fasting conditions.
started
Mar 1, 2004
primary completion
Apr 1, 2004
completion
Apr 1, 2004
last updated
Apr 24, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Carvedilol Tablets (12.5 mg; Mylan) to Coreg® Tablets (12.5 mg; GSK) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol